COVID-19-associated Coagulopathy: Role of Vitamins D and K.

Autor:	Getachew B; Department of Pharmacology, Howard University College of Medicine, Washington, DC 20059, USA., Landis HE; Integrative Medicine Fellow, University of Arizona, Tucson, AZ, USA., Manaye KF; Department of Physiology and Biophysics, Howard University College of Medicine, Washington, DC, USA., Tizabi Y; Department of Pharmacology, Howard University College of Medicine, Washington, DC 20059, USA.
Jazyk:	angličtina
Zdroj:	Current pharmaceutical biotechnology [Curr Pharm Biotechnol] 2023; Vol. 24 (3), pp. 401-410.
DOI:	10.2174/1389201023666220527110455
Abstrakt:	Recent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart attacks. Indeed, cardiovascular complications in COVID-19 account for 40% of mortality. Although there is no standard treatment protocol or guidelines for COVID-19, it is a common practice to use anti-inflammatory corticosteroids and anti-coagulants, especially for severe COVID-19 patients. It has also been confirmed that deficiencies of vitamin D and/or vitamin K can exacerbate premorbid cardiovascular and diabetes conditions associated with COVID-19, at least partially due to a higher incidence of coagulopathy. Here, we discuss the roles of vitamins D and K in general and in COVID-19-related coagulopathy. Moreover, the suggestion for proper supplementations of these vitamins in countering COVID-19 is provided. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu